Levetiracetam as an Alternative to Phenytoin for Prophylactic Use in Post-Traumatic Seizures: a Literature Review

Gabriela Nagatri, Dicky Arjuna Situmorang, Natanael Ramoti, Andre Marolop Pangihutan Siahaan, Rr. Suzy Indharty, Steven Tandean

Abstract


Traumatic brain injury (TBI) is a common concern for the causes of disability and mortality and it can cause post-traumatic seizure (PTS). Currently, Brain Trauma Foundation (BTF) recommends phenytoin (PHY) as early PTS prophylaxis for patients with severe TBI. The two most common drugs prescribed for PTS are levetiracetam (LEV) and PHY. However, PHY displays a wide array of disadvantages. LEV appears as a better alternative to PHY because of its easier administration, the absence of need for drug level monitoring, lower drug-drug interaction, and better side-effects profile. It is due to the linear elimination kinetics LEV had in comparison to PHY that have zero order pharmacokinetics. Theoretically, LEV is better than PHY. But according to prior studies, LEV and PHY have comparable efficacy at preventing PTS in the early stages. Furthermore, the current evidence is insufficient to definitely recommend LEV over PHY in terms of effectiveness and adverse effects. This study aimed to analyze levetiracetam as an alternative to phenytoin for prophylactic use in post-traumatic seizure.

Keywords


Levetiracetam, phenytoin, prophylaxis, post-traumatic seizure, traumatic brain injury

Full Text:

PDF

References


Haarbauer-Krupa J, Pugh MJ, Prager EM, Harmon N, Wolfe J, Yaffe K. Epidemiology of chronic effects of traumatic brain injury. J Neurotrauma. 2021;38(23):3235–47.

Amin TA, Nerenberg SF, Elsawy OA, Wang A, Johnston JP. Evaluation of levetiracetam for early post-traumatic seizure prophylaxis: A level II trauma center experience. Surgeon. 2023;21(2):e78–82.

Karamian A, Farzaneh H, Taheri M, Seifi A. Effectiveness of Levetiracetam versus phenytoin in preventing seizure in traumatic brain injury patients: A systematic review and meta-analysis. Clin Neurol Neurosurg [Internet]. 2024;240(March):108251. Available from: https://doi.org/10.1016/j.clineuro.2024.108251

Mengi T, Yılmaz B, Koca U, Gökmen AN. Phenytoin versus levetiracetam for posttraumatic seizure prophylaxis. Turkish J Intensive Care. 2022;20(4):201–6.

Ali A, Khizar A, Ahmed W, Yadav PK, Ali A, Khizar A, et al. The efficacy of Levetiracetam compared to phenytoin in prevention of post- traumatic seizures. A prospective cohort study from a low-middle-income country. Rom Neurosurg. 2023;478– 84.

Fordington S, Manford M. A review of seizures and epilepsy following traumatic brain injury. J Neurol [Internet]. 2020;267(10):3105–11. Available from: https://doi.org/10.1007/s00415-020-09926-w

Xu JC, Shen J, Shao WZ, Tang LJ, Sun YZ, Zhai XF, et al. The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis. Brain Inj. 2016;30(9):1054–61.

Yerram S, Katyal N, Premkumar K, Nattanmai P, Newey CR. In brief. Seal Technol. 2006;1–10.

Candy N, Tsimiklis C, Poonnoose S, Trivedi R. The use of antiepileptic medication in early post traumatic seizure prophylaxis at a single institution. J Clin Neurosci [Internet]. 2019;69:198–205. Available from: https://doi.org/10.1016/j.jocn.2019.07.066

Gapp J, Tariq A, Chandra S. Acute pancreatitis. StatPearls [Internet]. 2023 Feb 9 [cited 2023 Dec 20]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK482468/

McGovern Medical School. Post-traumatic seizure prophylaxis in patients with traumatic brain injury clinical practice guideline. Texas: The University of Texas Health Science Center at Houston. 2024. Available from : https://med.uth.edu/surgery/ -traumaticseizure-prophylaxis-in-patients-with-traumatic-brain-injury-clinical-practice-guideline/

Keppel Hesselink JM. Phenytoin: a step by step insight into its multiple mechanisms of action—80 years of mechanistic studies in neuropharmacology. J Neurol. 2017;264(9):2043–7. Doi: 10.1007/s00415-017-8465-4

Patocka J, Wu Q, Nepovimova E, Kuca K. Phenytoin – An anti-seizure drug: Overview of its chemistry, pharmacology and toxicology. Food Chem Toxicol [Internet]. 2020;142(April):111393. Available from: https://doi.org/10.1016/j.fct.2020.111393

Bounthavong M, Kazerooni. Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injury. Clin Outcomes Res [Internet]. 2010;15. Available from: https://doi.org/10.2147/ceor.s8965

Lilly LS. Pathophysiology of heart disease 6th Edition. 2016.

Ohman K, Kram B, Schultheis J, Sigmon J, Kaleem S, Yang Z, et al. Evaluation of levetiracetam dosing strategies for seizure prophylaxis following traumatic brain injury. Neurocrit Care [Internet]. 2023;38(2):345–55. Available from: https://doi.org/10.1007/s12028-022-01599-9

Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology [Internet]. 2020;168(September 2019):107966. Available from: https://doi.org/10.1016/j.neuropharm.2020.107966

Deshpande LS, DeLorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol. 2014;5(11):1–5. Doi: 10.3389/fneur.2014.00011

Bianchi V, Arfini C, Vidali M. Therapeutic drug monitoring of levetiracetam. Ther Drug Monit. 2014;36(5):681–5. Doi: 10.1097/FTD.0000000000000060

Lindberg R. Traumatic brain injury Guidelines 2022 Tele-Rehabilitation Guidelines management of seizures in the patient with traumatic brain injury. 2022. Available from: https://medicine.uams.edu/pmr/wp-content/uploads/sites/3/2022/03/Guidelines-TBI-Seizures-2022.pdf




DOI: https://doi.org/10.24244/jni.v13i3.622

Refbacks

  • There are currently no refbacks.


                                    

 

JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License